TY - JOUR
T1 - Pancreatic cancer in patients with autoimmune pancreatitis
T2 - A scoping review
AU - Macinga, Peter
AU - Bajer, Lukas
AU - Del Chiaro, Marco
AU - Chari, Suresh T.
AU - Dite, Petr
AU - Frulloni, Luca
AU - Ikeura, Tsukasa
AU - Kamisawa, Terumi
AU - Kubota, Kensuke
AU - Naitoh, Itaru
AU - Okazaki, Kazuichi
AU - Pezzilli, Raffaele
AU - Vujasinovic, Miroslav
AU - Spicak, Julius
AU - Hucl, Tomas
AU - Lӧhr, Matthias
N1 - Publisher Copyright:
© 2021 IAP and EPC
PY - 2021/8
Y1 - 2021/8
N2 - Background: Chronic pancreatitis is a known risk factor of pancreatic cancer (PDAC). A similar association has been suggested but not demonstrated for autoimmune pancreatitis (AIP). Objective: The aim of our study was to identify and analyse all published cases of AIP and PDAC co-occurrence, focusing on the interval between the diagnoses and the cancer site within the pancreas. Methods: Relevant studies were identified through automatic searches of the MEDLINE, EMBASE, Scopus, and Web of Science databases, and supplemented by manual checks of reference lists in all retrieved articles. Missing/unpublished data were obtained from the authors of relevant publications in the form of pre-prepared questionnaires. Results: A total of 45 cases of PDAC in AIP patients were identified, of which 12 were excluded from the analysis due to suspicions of duplicity or lack of sufficient data. Thirty-one patients (94%) had type 1 AIP. Synchronous occurrence of PDAC and AIP was reported in 11 patients (33%), metachronous in 22 patients (67%). In the metachronous group, the median period between diagnoses was 66.5 months (2–186) and a majority of cancers (86%) occurred more than two years after AIP diagnosis. In most patients (70%), the cancer originated in the part of the pancreas affected by AIP. Conclusions: In the literature, there are reports on numerous cases of PDAC in AIP patients. PDAC is more frequent in AIP type 1 patients, typically metachronous in character, and generally found in the part of the pancreas affected by AIP.
AB - Background: Chronic pancreatitis is a known risk factor of pancreatic cancer (PDAC). A similar association has been suggested but not demonstrated for autoimmune pancreatitis (AIP). Objective: The aim of our study was to identify and analyse all published cases of AIP and PDAC co-occurrence, focusing on the interval between the diagnoses and the cancer site within the pancreas. Methods: Relevant studies were identified through automatic searches of the MEDLINE, EMBASE, Scopus, and Web of Science databases, and supplemented by manual checks of reference lists in all retrieved articles. Missing/unpublished data were obtained from the authors of relevant publications in the form of pre-prepared questionnaires. Results: A total of 45 cases of PDAC in AIP patients were identified, of which 12 were excluded from the analysis due to suspicions of duplicity or lack of sufficient data. Thirty-one patients (94%) had type 1 AIP. Synchronous occurrence of PDAC and AIP was reported in 11 patients (33%), metachronous in 22 patients (67%). In the metachronous group, the median period between diagnoses was 66.5 months (2–186) and a majority of cancers (86%) occurred more than two years after AIP diagnosis. In most patients (70%), the cancer originated in the part of the pancreas affected by AIP. Conclusions: In the literature, there are reports on numerous cases of PDAC in AIP patients. PDAC is more frequent in AIP type 1 patients, typically metachronous in character, and generally found in the part of the pancreas affected by AIP.
KW - Autoimmune pancreatitis
KW - Chronic pancreatitis
KW - Immunoglobulin G4-Related disease
KW - Malignancy
KW - Pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=85103338114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103338114&partnerID=8YFLogxK
U2 - 10.1016/j.pan.2021.03.007
DO - 10.1016/j.pan.2021.03.007
M3 - Article
C2 - 33775564
AN - SCOPUS:85103338114
SN - 1424-3903
VL - 21
SP - 928
EP - 937
JO - Pancreatology
JF - Pancreatology
IS - 5
ER -